Popular Articles

Increased Vascular Endothelial Growth Factor Expression In Patients With Bladder Pain Syndrome/Interstitial Cystitis
UroToday.com - Angiogenesis is thought to be important in many chronic inflammatory disorders, including diabetic retinopathy, atherosclerosis, and inflammatory bowel disease. It has also been suggested that the angiogenic components of these diseases contribute to and exacerbate disease conditions. Increased levels of vascular endothelial growth factor (VEGF) have been detected in patients with asthma and have been shown to be correlated with the severity of the disease. Anti-VEGF therapy has been shown to ameliorate inflammation in animal models of chronic inflammatory bowel disease. This background forms the prelude to a very interested study by Kiuchi and colleagues from Osaka, Japan.
generic viagra online
Embryo Movement Stimulates Joint Formation
A new study uncovers a molecular mechanism that explains why joints fail to develop in embryos with paralyzed limbs. The research, published by Cell Press in the May issue of the journal Developmental Cell, answers a longstanding question about the influence of muscle activity on developing joints and underscores the critical contribution of movement to regulation of a signaling pathway that is important during development and beyond.
News of the day
FDA Approves Vaccine For Seasonal Influenza
The US Food and Drug Administration (FDA) announced yesterday that it has approved a vaccine for 2009-2010 seasonal influenza in the United
Health Insurance

MEDai Helps Medicare Part D Sponsors Adhere To CMS Medication Therapy Management Initiative

MEDai, Inc., headquartered in Orlando, FL, a leading provider of advanced solutions for healthcare that utilize award-winning predictive analytics, announced that its solutions are actively assisting Medicare Part D benefit sponsors with the Centers for Medicare & Medicaid Services mandate, calling all Medicare Part D to offer members a medication therapy management (MTM) program. MEDai"s solutions grant Part D benefit sponsors the ability to identify MTM members who meet client-specific requirements as well as stratify patients using CMS mandated rules. The user-friendly applications collect, analyze and report on data that facilitates sponsor adherence to this new initiative. Clients can specify participation criteria; analyze the necessary data; and produce patient encounter documentation, patient and provider communication, and reporting documents. "MEDai continues to develop solutions that address immediate needs in the payor market," said Swati Abbott, president of MEDai. "Our solutions offer numerous advantages, including the ability for Part D benefit sponsors to modify or create guidelines to identify members for MTM program participation, monitor the medication compliance and gaps in therapy for those members, and deliver that information to the point-of-care or to a member"s personal health record," she added. About MEDai MEDai, Inc. is a subsidiary of Elsevier, a world-leading publisher of scientific, technical and medical information products and services. For more than a decade, MEDai has been offering award-winning solutions for the improvement of healthcare delivery. Utilizing cutting-edge technology, payors and care management organizations are able to predict patients at risk, identify cost drivers for their high-risk population, forecast future health plan costs, evaluate patient patterns over time and improve outcomes. MEDai, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):